Flamel Tech. (FLML) Reports Q4 Loss of $0.11
More News related to FLML
- Flamel Technologies Announces Projected Release Date of Third Quarter Results; Conference Call
- Flamel Technologies Announces Licensing Agreement with Pfizer
- Flamel Technologies to Present at UBS Global Life Sciences Conference
- Baxter (BAX) and Flamel Technologies (FLML) Announce Collaboration to Formulate Longer Acting Forms of Blood Clotting Factors
- Flamel Tech. (FLML) Reports Q4 Loss of $0.11
More News related to Earnings
- Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
Flamel Technologies (NASDAQ: FLML) reports Q4 loss of $0.11, versus the analyst estimate of ($0.02) and compared to a loss of $0.25 in the same quarter last year. Revenues for the quarter were $9.5 million, versus the consensus of $12.74 million. (only 1 analyst covers the stock)
Related Categories
EarningsStocks Mentioned
-0.58Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
